Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 6/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221807 | 0.83 | AAK1 (0.41) | LIPE | |
| SCHEMBL1053651 | 0.81 | LIPE (0.49) | LIPEHIF1ACA1CA2CA9 | |
| SCHEMBL1061781 | 0.81 | POLB (0.40) | LIPE | |
| SCHEMBL28727225 | 0.79 | AKR1C4 (0.37) | LIPEGPR35CA1CA2 | |
| SCHEMBL15172109 | 0.78 | LIPE (0.32) | LIPEEGFR | |
| SCHEMBL23409438 | 0.76 | LPL (0.35) | EGFR | |
| SCHEMBL16632449 | 0.76 | CA1 (0.37) | LIPEPDGFRBKDRHIF1ACXCR2 | |
| SCHEMBL15271999 | 0.75 | CA1 (0.36) | LIPEPDGFRBKDRHIF1ACXCR2 | |
| SCHEMBL17770661 | 0.75 | CXCR2 (0.34) | LIPEPDGFRBKDRGPR35HIF1A | |
| SCHEMBL22777316 | 0.75 | HIF1A (0.35) | LIPEPDGFRBKDRHIF1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850229-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2727918-B1 | Compounds and Compositions as Protein Kinase Inhibitors | ARRAY BIOPHARMA INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160280686-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2016-09-29 | — | — | US | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280686-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | LIPE 3394/4885PDGFRB 1523/4885KDR 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.